Common Contracts

6 similar Underwriting Agreement contracts by Amgen Inc

AMGEN INC. $750,000,000 3.000% SENIOR NOTES DUE 2029 $1,000,000,000 3.350% SENIOR NOTES DUE 2032 $1,000,000,000 4.200% SENIOR NOTES DUE 2052 $1,250,000,000 4.400% SENIOR NOTES DUE 2062 Underwriting Agreement
Underwriting Agreement • February 22nd, 2022 • Amgen Inc • Biological products, (no disgnostic substances) • New York

Amgen Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of $750,000,000 principal amount of its 3.000% Senior Notes due 2029 (the “2029 Notes”), $1,000,000,000 principal amount of its 3.350% Senior Notes due 2032 (the “2032 Notes”), $1,000,000,000 principal amount of its 4.200% Senior Notes due

AutoNDA by SimpleDocs
AMGEN INC. $1,250,000,000 1.650% SENIOR NOTES DUE 2028 $1,250,000,000 2.000% SENIOR NOTES DUE 2032 $1,150,000,000 2.800% SENIOR NOTES DUE 2041 $1,350,000,000 3.000% SENIOR NOTES DUE 2052 Underwriting Agreement
Underwriting Agreement • August 9th, 2021 • Amgen Inc • Biological products, (no disgnostic substances) • New York

Amgen Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of $1,250,000,000 principal amount of its 1.650% Senior Notes due 2028 (the “2028 Notes”), $1,250,000,000 principal amount of its 2.000% Senior Notes due 2032 (the “2032 Notes”), $1,150,000,000 principal amount of its 2.800% Senior Notes due 2041 (the “2041 Notes”) and $1,350,000,000 principal amount of its 3.000% Senior Notes due 2052 (the “2052 Notes,” and together with the 2028 Notes, the 2032 Notes and the 2041 Notes, the “Securities”) to be issued pursuant to the provisions of an Indenture dated as

AMGEN INC. $1,000,000,000 2.200% SENIOR NOTES DUE 2027 $1,250,000,000 2.300% SENIOR NOTES DUE 2031 $750,000,000 3.150% SENIOR NOTES DUE 2040 $1,000,000,000 3.375% SENIOR NOTES DUE 2050 Underwriting Agreement
Underwriting Agreement • May 6th, 2020 • Amgen Inc • Biological products, (no disgnostic substances) • New York

Amgen Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of $1,000,000,000 additional principal amount of its existing 2.200% Senior Notes due 2027 (the “2027 Reopening Notes”), $1,250,000,000 principal amount of its 2.300% Senior Notes due 2031 (the “2031 Notes”), $750,000,000 additional principal amount of its existing 3.150% Senior Notes due 2040 (the “2040 Reopening Notes”) and $1,000,000,000 additional principal amount of its existing 3.375% Senior Notes due 2050 (the “2050 Reopening Notes,” and together with the 2027 Reopening Notes, the 2031 Notes and the 2040 Reopening Notes, the “Securities”).

AMGEN INC. $850,000,000 1.250% SENIOR NOTES DUE 2017 $1,400,000,000 2.200% SENIOR NOTES DUE 2019 $1,400,000,000 3.625% SENIOR NOTES DUE 2024 $600,000,000 SENIOR FLOATING RATE NOTES DUE 2017 $250,000,000 SENIOR FLOATING RATE NOTES DUE 2019 Underwriting...
Underwriting Agreement • May 22nd, 2014 • Amgen Inc • Biological products, (no disgnostic substances) • New York

Amgen Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of $850,000,000 principal amount of the 1.250% Senior Notes due 2017 of the Company (the “2017 Notes”), an aggregate of $1,400,000,000 principal amount of the 2.200% Senior Notes due 2019 of the Company (the “2019 Notes”), an aggregate of $1,400,000,000 principal amount of the 3.625% Senior Notes due 2024 of the Company (the “2024 Notes”), an aggregate of $600,000,000 principal amount of the Senior Floating Rate Notes due 2017 of the Company (the “2017 Floating Notes”) and an aggregate of $250,000,000 principal amount of the Senior Floating Rate Notes due 2019 of the Company (the “2019 Floating Notes”, and together with the 2017 Notes, the 2019 Notes, the 2024 Notes and the 2017 Floating Notes, collectively, the “Securities”) to be issued pursuant to the provisions of an Indent

AMGEN INC. $750,000,000 2.30% SENIOR NOTES DUE 2016 $1,000,000,000 4.10% SENIOR NOTES DUE 2021 $1,250,000,000 5.65% SENIOR NOTES DUE 2042 Underwriting Agreement
Underwriting Agreement • June 30th, 2011 • Amgen Inc • Biological products, (no disgnostic substances) • New York

Amgen Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of $750,000,000 principal amount of the 2.30% Senior Notes due 2016 of the Company (the “2016 Notes”), an aggregate of $1,000,000,000 principal amount of the 4.10% Senior Notes due 2021 of the Company (the “2021 Notes”) and an aggregate of $1,250,000,000 principal amount of the 5.65% Senior Notes due 2042 of the Company (the “2042 Notes”, together with the 2016 Notes and the 2021 Notes, collectively, the “Securities”) to be issued pursuant to the provisions of an Indenture, dated as of August 4, 2003 (the “Indenture”), between the Company and the Bank of New York Mellon, as successor to JPMorgan Chase Bank, N.A., as Trustee (the “Trustee”).

AMGEN INC. $500,000,000 6.15% SENIOR NOTES DUE 2018 $500,000,000 6.90% SENIOR NOTES DUE 2038 Underwriting Agreement
Underwriting Agreement • May 23rd, 2008 • Amgen Inc • Biological products, (no disgnostic substances) • New York

Amgen Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of $500,000,000 principal amount of the 6.15% Senior Notes due 2018 of the Company (the “2018 Notes”) and an aggregate of $500,000,000 principal amount of the 6.90% Senior Notes due 2038 of the Company (the “2038 Notes” and, together with the 2018 Notes, the “Securities”) to be issued pursuant to the provisions of an Indenture, dated as of August 4, 2003 (the “Indenture”), between the Company and the Bank of New York, as successor to JPMorgan Chase Bank, N.A., as Trustee (the “Trustee”).

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!